$19.75
0.381.96%
Pre-Market: Jul 19, 4:23 PM EDT
15 minutes delayed
Comments
Loading...
Pacira BioSciences
PCRXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Pacira BioSciences (NASDAQ:PCRX) Stock, Analyst Ratings, Price Targets, Forecasts
Pacira BioSciences Inc has a consensus price target of $56 based on the ratings of 15 analysts. The high is $94 issued by Wedbush on February 28, 2022. The low is $25 issued by Barclays on July 3, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Barclays, and Needham on July 3, 2024, July 3, 2024, and July 2, 2024, respectively. With an average price target of $36.67 between Piper Sandler, Barclays, and Needham, there's an implied 85.65% upside for Pacira BioSciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Barclays
Needham
HC Wainwright & Co.
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Pacira BioSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/03/2024 | Buy Now | 112.66% | Piper Sandler | David Amsellem | $42 → $42 | Maintains | Overweight | Get Alert |
| 07/03/2024 | Buy Now | 26.58% | Barclays | Balaji Prasad | $38 → $25 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/02/2024 | Buy Now | 117.72% | Needham | Serge Belanger | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 07/02/2024 | Buy Now | 188.61% | HC Wainwright & Co. | Oren Livnat | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 188.61% | HC Wainwright & Co. | Oren Livnat | → $57 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 92.41% | Barclays | Balaji Prasad | $40 → $38 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | 117.72% | Needham | Serge Belanger | $45 → $43 | Maintains | Buy | Get Alert |
| 04/09/2024 | Buy Now | 127.85% | Needham | Serge Belanger | → $45 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 127.85% | JP Morgan | Hardik Parikh | → $45 | Assumes | → Overweight | Get Alert |
| 03/04/2024 | Buy Now | 188.61% | HC Wainwright & Co. | Oren Livnat | → $57 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 127.85% | RBC Capital | Gregory Renza | $53 → $45 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 127.85% | Needham | Serge Belanger | → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/08/2024 | Buy Now | 188.61% | Wedbush | Andreas Argyrides | → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2023 | Buy Now | 112.66% | Raymond James | Gary Nachman | → $42 | Initiates | → Outperform | Get Alert |
| 11/06/2023 | Buy Now | 188.61% | HC Wainwright & Co. | Oren Livnat | $63 → $57 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 112.66% | Piper Sandler | David Amsellem | $50 → $42 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 193.67% | RBC Capital | Gregory Renza | $67 → $58 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 127.85% | Needham | Serge Belanger | $52 → $45 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 188.61% | Barclays | Balaji Prasad | $60 → $57 | Maintains | Overweight | Get Alert |
| 10/03/2023 | Buy Now | 244.3% | RBC Capital | Gregory Renza | → $68 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | 153.16% | Piper Sandler | David Amsellem | $60 → $50 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | 178.48% | Truist Securities | Les Sulewski | $60 → $55 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 244.3% | RBC Capital | Gregory Renza | $70 → $68 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | 153.16% | TD Cowen | Boris Peaker | → $50 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | 218.99% | HC Wainwright & Co. | Oren Livnat | $68 → $63 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 163.29% | Needham | Serge Belanger | $60 → $52 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 244.3% | HC Wainwright & Co. | Oren Livnat | $71 → $68 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | 203.8% | Piper Sandler | David Amsellem | → $60 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 264.56% | RBC Capital | Gregory Renza | $75 → $72 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 259.49% | HC Wainwright & Co. | Oren Livnat | → $71 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 213.92% | Piper Sandler | David Amsellem | → $65 | Maintains | Overweight | Get Alert |
| 04/20/2023 | Buy Now | 203.8% | Needham | Serge Belanger | → $60 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 284.81% | RBC Capital | Gregory Renza | $80 → $76 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 259.49% | HC Wainwright & Co. | Oren Livnat | $69 → $71 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 203.8% | Needham | Serge Belanger | $63 → $60 | Maintains | Buy | Get Alert |
| 02/10/2023 | Buy Now | 249.37% | HC Wainwright & Co. | Oren Livnat | $76 → $69 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | 203.8% | Wedbush | Andreas Argyrides | → $60 | Assumes | → Outperform | Get Alert |
| 01/06/2023 | Buy Now | 163.29% | BMO Capital | Gary Nachman | $60 → $52 | Maintains | Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 218.99% | Needham | Serge Belanger | $66 → $63 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | 203.8% | BMO Capital | Gary Nachman | $66 → $60 | Maintains | Market Perform | Get Alert |
| 11/04/2022 | Buy Now | 284.81% | HC Wainwright & Co. | Oren Livnat | $83 → $76 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 274.68% | Needham | Serge Belanger | $76 → $74 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 234.18% | Jefferies | Glen Santangelo | → $66 | Assumes | → Buy | Get Alert |
| 08/04/2022 | Buy Now | 284.81% | Piper Sandler | David Amsellem | $80 → $76 | Maintains | Overweight | Get Alert |
| 07/21/2022 | Buy Now | 305.06% | Piper Sandler | David Amsellem | $84 → $80 | Maintains | Overweight | Get Alert |
| 06/15/2022 | Buy Now | 284.81% | Needham | Serge Belanger | $84 → $76 | Maintains | Buy | Get Alert |
| 02/28/2022 | Buy Now | 375.95% | Wedbush | Liana Moussatos | $97 → $94 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | 355.7% | HC Wainwright & Co. | Oren Livnat | $86 → $90 | Maintains | Buy | Get Alert |
| 01/19/2022 | Buy Now | 386.08% | Barclays | Balaji Prasad | $92 → $96 | Maintains | Overweight | Get Alert |
| 11/05/2021 | Buy Now | 365.82% | Barclays | — | — | Maintains | Overweight | Get Alert |
| 11/04/2021 | Buy Now | 335.44% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
| 10/18/2021 | Buy Now | 325.32% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
| 10/12/2021 | Buy Now | 305.06% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
| 10/01/2021 | Buy Now | 360.76% | Barclays | Balaji Prasad | — | Maintains | Overweight | Get Alert |
| 08/04/2021 | Buy Now | 325.32% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
| 07/26/2021 | Buy Now | 279.75% | JP Morgan | Christopher Neyor | — | Upgrade | Neutral → Overweight | Get Alert |
FAQ
What is the target price for Pacira BioSciences (PCRX) stock?
The latest price target for Pacira BioSciences (NASDAQ:PCRX) was reported by Piper Sandler on July 3, 2024. The analyst firm set a price target for $42.00 expecting PCRX to rise to within 12 months (a possible 112.66% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacira BioSciences (PCRX)?
The latest analyst rating for Pacira BioSciences (NASDAQ:PCRX) was provided by Piper Sandler, and Pacira BioSciences maintained their overweight rating.
When was the last upgrade for Pacira BioSciences (PCRX)?
The last upgrade for Pacira BioSciences Inc happened on August 3, 2023 when TD Cowen raised their price target to $50. TD Cowen previously had a market perform for Pacira BioSciences Inc.
When was the last downgrade for Pacira BioSciences (PCRX)?
The last downgrade for Pacira BioSciences Inc happened on July 3, 2024 when Barclays changed their price target from $38 to $25 for Pacira BioSciences Inc.
When is the next analyst rating going to be posted or updated for Pacira BioSciences (PCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
Is the Analyst Rating Pacira BioSciences (PCRX) correct?
While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a maintained with a price target of $42.00 to $42.00. The current price Pacira BioSciences (PCRX) is trading at is $19.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.